Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
 Drug News
Search by keywords and publication date
Keywords:   any keywords all keywords
Pub Date:   From
  To    
   
 Search Results:
1 to 25 of 278 results
Paper Alert—HORIZON Trial Data Published
22  January 2013. Researchers have formally published the results of the Phase 3 trial of Dimebon®, aka latrepirdine, in Huntington’s disease patients...

  
Cut to the Chase: Therapies Go Directly to Central Nervous System
22  January 2013. A growing number of neurosurgeons are inserting needles, catheters, and capsules into the brain or spinal cord, hoping to alleviate AD and other neurodegenerative conditions...

  
NIH Funds Four Clinical Trials in ADCS Renewal
18  January 2013. The National Institutes of Health announced that it will fund the Alzheimer’s Disease Cooperative Study to conduct four new clinical studies over the next five years...

  
Solanezumab Selected for Alzheimer’s A4 Prevention Trial
18  January 2013. Researchers announced the selection of solanezumab as the first therapeutic drug to be evaluated in the A4 prevention clinical trial...

  
Alzforum’s Top 12 of 2012
31  December 2012. Here’s hoping that this year’s 12 trends of Alzheimer’s may have staying power—enough to put the search for therapies on a stronger footing...

  
Tau-Targeting Drug Davunetide Washes Out in Phase 3 Trials
21  December 2012. Allon Therapeutics Inc. announced that its drug candidate davunetide failed to show efficacy for progressive supranuclear palsy (PSP) in a Phase 2/3 trial...

  
Q&A With Merck’s Johan Luthman
14  December 2012. Merck’s BACE inhibitor development program began enrolling last month for an 18-month Phase 2/3 trial of its lead compound (MK-8931) in mild to moderate AD...

  
Solanezumab Heads for New Phase 3 Trial
13  December 2012. Eli Lilly announced yesterday that it plans to conduct a new Phase 3 trial of its anti-amyloid antibody, solanezumab...

  
Drug Company Halts Development of γ-Secretase Inhibitor Avagacestat
11  December 2012. Bristol-Myers Squibb recently announced that it will halt all clinical development of its γ-secretase inhibitor avagacestat...

  
Merck Launches Largest Trial of BACE Inhibitor in AD
7  December 2012. Merck announced this week that it has begun enrolling for the largest clinical trial of a β-secretase (BACE1) inhibitor in Alzheimer’s disease patients...

  
Déjà Vu? AD Patients Again Look Worse on γ-Secretase Inhibitor
21  November 2012. In a Phase 2 trial of avagacestat, AD patients who took high doses suffered more adverse effects and appeared to fare worse cognitively than those on placebo...

  
DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor
10  October 2012. Today, scientists of DIAN's Trials Unit announced their drug choices for trials to try to prevent dementia in people who have inherited autosomal-dominant mutations...

  
The Solanezumab Benefit: Oh, So Small, But Probably Real
9  October 2012. Prospects for Alzheimer’s immunotherapy appear to have brightened...

  
Bapineuzumab Phase 3: Target Engagement, But No Benefit
12  September 2012. Bapineuzumab prevents accumulation of Aβ in the brain and lowers phospho-tau (p-tau) in cerebrospinal fluid (CSF), according to analysis...

  
Paper Alert—GuidAge Trial Data on Ginkgo Biloba Published
11  September 2012. It did not pass muster in a large clinical trial in the U.S., and now a similar study in Europe concludes that ginkgo biloba extract does nothing to prevent the onset of AD...

  
Phase 3 Solanezumab Trials "Fail"—Is There a Silver Lining?
24  August 2012. Eli Lilly and Company announced today that solanezumab did not reach its primary endpoints in either of two trials in patients with mild to moderate AD...

  
Anticonvulsants Reverse AD-like Symptoms in Transgenic Mice
14  August 2012. Could anti-epileptic drugs be the next hope for treating and even preventing Alzheimer’s disease symptoms?...

  
Clinical Trials of Intravenous Bapineuzumab Halted
8  August 2012. Janssen Alzheimer Immunotherapy will discontinue all studies of intravenous bapineuzumab, an amyloid-β antibody, in patients with mild to moderate Alzheimer’s disease...

  
Q&A With Roche’s CNS Leader Luca Santarelli
25  July 2012. Gabrielle Strobel met up with Luca Santarelli, who has moved into drug discovery research at Roche/Genentech and now oversees the AD therapy development program, among others...

  
No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
23  July 2012. Pfizer conceded that results of the first of four Phase 3 trials of intravenous bapineuzumab failed to meet its co-primary endpoints in patients with mild to moderate AD...

  
Novel Drug Knocks Aβ Off Synapses, Reduces Toxicity
20  July 2012. In AD therapy, it may be time for an alternative target to shine: the α7 nicotinic acetylcholine receptor...

  
Therapy Reported to Boost Cognition in Phase 2 Clinical Trial
1  June 2012. This week, H. Lundbeck A/S, an international pharmaceutical company based in Denmark, announced positive results of a Phase 2 trial...

  
Epilepsy Drug Calms the Hippocampus, Aids Memory
9  May 2012. Research suggests that the hippocampus goes into overdrive in people who may be on the path to Alzheimer's disease...

  
Keystone: Therapies Around ApoE—Has Their Time Come?
5  April 2012. Even though ApoE stands head and shoulders above other genetic risk factors for late-onset AD, few therapeutic strategies aimed at ApoE have made it to clinical trials...

  
Bapineuzumab Crops CSF Tau Levels
4  April 2012. The concentration of tau in the cerebrospinal fluid drops with bapineuzumab treatment...

  
1 to 25 of 278 results
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Forum Calendar

Biospace Beat

See related news on Alzheimer disease on the BioSpace website.
Coalition Against Major Diseases (CAMD)
Visit C-Path's Coalition Against Major Diseases to learn about its collaborative efforts in Alzheimer's and Parkinson's.
C-Path
AlzGene
PDGene
SZGene
MSGene
ALSGene
An up-to-date collection of all published genetic association studies.
AlzRisk: An AD Epidemiology Database
The AlzRisk Epidemiology Database provides a publicly available collection of published studies on the impact of putative environmental risk factors and protective factors related to Alzheimer disease in longitudinal cohort studies.
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Rock Stars of Science

Check out Geoffrey Beene Gives Back®'s Rocks Stars of Science campaign to bring rock stars and science idols together to share their passion for global health and disease prevention.
Rock Stars of Science
ALS Forum

The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
ALS Forum
Brain on Fire
PIB PET in early AD patient reveals amyloid in cortex and deep brain areas.[Video courtesy of Scott Ziolko and the Pittsburgh Amyloid Imaging Group]
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad